RhyGaze is a biotechnology company based in Basel, Switzerland and Philadelphia, Pa., focused on developing gene therapies for retinal diseases that cause blindness. Its lead clinical candidate is a novel gene therapy for optogenetic vision restoration. The company was founded on intellectual property exclusively licensed from the Institute of Molecular and Clinical Ophthalmology Basel (IOB); IOB scientists Botond Roska, Bence György and Charles Gubser are scientific founders. RhyGaze plans to use funding to complete formal pharmacology and toxicology testing, run a non‑interventional observational study to assess potential clinical endpoints, and initiate a first‑in‑human clinical trial to evaluate safety, tolerability and potential efficacy. The company is led by CEO Dr. Katherine High and aims to translate preclinical data from IOB into clinical outcomes. Financially, RhyGaze recently raised significant Series A capital to advance its lead program, supplementing an earlier seed investment from its founding backers.

Total raised

$86M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2025